HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity

Maria Pernas; Victor Sanchez-Merino; Concepcion Casado; Alberto Merino-Mansilla; Isabel Olivares; Eloisa Yuste; Cecilio Lopez-Galindez

doi:10.1371/journal.pone.0134054

HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity

PLoS One. 2015 Aug 10;10(8):e0134054. doi: 10.1371/journal.pone.0134054. eCollection 2015.

Authors

Maria Pernas¹, Victor Sanchez-Merino², Concepcion Casado¹, Alberto Merino-Mansilla², Isabel Olivares¹, Eloisa Yuste², Cecilio Lopez-Galindez¹

Affiliations

¹ Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III, Majadahonda, Madrid 28220, Spain.
² AIDS Research Unit, Institut d´Investigacions Biomediquès August Pi i Sunyer, Barcelona, Spain; HIVACAT, Barcelona, Spain.

Abstract

This study evaluated the neutralization breadth in dually infected (DI) HIV-1 long-term non-progressor elite controller patients (LTNP-EC) using a representative minipanel of 6 viruses from 5 different subtypes. Our results showed an improved neutralization breadth in DI LTNP-EC patients when compared with matched LTNP single-infected patients. The role of viral diversity in neutralization was estimated with the Shannon Entropy and the p-distance in viral quasispecies. We found a positive correlation between neutralization breadth and diversity within the viral quasispecies. This correlation could explain why a group of LTNP-EC patients developed a broad neutralizing response despite having undetectable levels of viremia.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing / immunology*
Entropy
Follow-Up Studies
Genetic Variation
HIV Antibodies / immunology*
HIV Infections / immunology
HIV Infections / virology
HIV Long-Term Survivors*
HIV-1 / classification*
HIV-1 / immunology
Humans
Neutralization Tests
Phylogeny
Viral Load
Viremia / virology*

Substances

Antibodies, Neutralizing
HIV Antibodies

Grants and funding

Work in CNM is supported by grants from Fundacion para la Investigación del Sida en España (www.fipse.es) and (PI 13/02269) Fondo de Investigación Sanitaria (ISCIII) (www.isciii.es) to CL. Red de Investigación en SIDA www.retic-ris.net to CL. A grant RD12/0017/0036 to CL as part of the Plan Nacional R D+I and cofinanced by ISCIII (www.isciii.es) - Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). CL IDIBAPS work was supported by a grant (RYC-2007-00788) to EY from the Ministerio de Ciencia y Tecnologia www.micinn.es, a grant (PS09/01459) to EY from the Fondo de Investigaciones Sanitarias (ISCIII) (www.isciii.es).